KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Operating Leases (2023 - 2025)

Biocryst Pharmaceuticals' Operating Leases history spans 3 years, with the latest figure at $8.6 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 8.17% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $8.6 million, up 8.17%, while the annual FY2025 figure was $8.6 million, 8.17% up from the prior year.
  • Operating Leases reached $8.6 million in Q4 2025 per BCRX's latest filing, down from $8.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $12.2 million in Q3 2023 to a low of $7.8 million in Q1 2025.
  • Average Operating Leases over 3 years is $8.8 million, with a median of $8.4 million recorded in 2023.
  • The largest YoY upside for Operating Leases was 15.06% in 2024 against a maximum downside of 34.15% in 2024.
  • A 3-year view of Operating Leases shows it stood at $8.4 million in 2023, then dropped by 5.55% to $7.9 million in 2024, then grew by 8.17% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Operating Leases are $8.6 million (Q4 2025), $8.8 million (Q3 2025), and $8.5 million (Q2 2025).